Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 2/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15991475 | 0.83 | ALDH1A1 (0.57) | BACE1BACE2SMN1; SMN2SCN9A | |
| SCHEMBL26025143 | 0.83 | PLK1 (0.46) | HRH3PLK1P4HTMPARP1HPGD | |
| SCHEMBL991921 | 0.82 | MAPK1 (0.57) | BACE1BACE2P4HTMPARP1HPGD | |
| SCHEMBL14903870 | 0.81 | PLK1 (0.55) | HRH3PLK1P4HTMHPGDSMN1; SMN2 | |
| SCHEMBL3169006 | 0.81 | PLK1 (0.45) | BACE1HRH3PLK1P4HTMPARP1 | |
| SCHEMBL25363419 | 0.80 | PLK1 (0.44) | HRH3PLK1P4HTMPARP1HPGD | |
| SCHEMBL16987810 | 0.80 | HRH3 (0.47) | HRH3PLK1P4HTMPARP1HPGD | |
| SCHEMBL991920 | 0.80 | P4HTM (0.63) | P4HTMTSHRHTTSMN1; SMN2 | |
| SCHEMBL6934524 | 0.79 | NPC1 (0.56) | BACE1BACE2P4HTMSMN1; SMN2 | |
| SCHEMBL9197238 | 0.79 | HRH3 (0.44) | HRH3PLK1P4HTMPARP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751886-B2 | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-05 | — | — | US | disclosed |
| US-20160130274-A1 | 4-AMINO-6-PHENYL-6,7-DIHYDRO[1,2,3]TRIAZOLO[1,5-A]PYRAZINE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130274-A1 | 4-AMINO-6-PHENYL-6,7-DIHYDRO[1,2,3]TRIAZOLO[1,5-A]PYRAZINE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885HRH3 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.